High Throughput Technologies: Determinants of the Immune Response to Cancer

Moderators:

Katherine L. Nathanson, MD
Perelman School of Medicine at the University of Pennsylvania

Paul Robbins, PhD
National Institutes of Health
Merging of distinct disciplines to ask critical questions in immunotherapy

- Can we identify inherited predictors of response and adverse events?
- Is the presence and burden of mutated proteins in the tumor predictive of response?
- Can single cell proteomics be used to predict therapeutic outcomes?
Integration of high throughput technologies into immunotherapy

Vonderheide & Nathanson, Nat Med 2013
Talks

• Use of high throughput sequencing to identify mutated tumor antigens
  – Paul Robbins, NIH/NCI
• Inherited genetic response
  – Kevin Brown, NIH/NCI
• Single cell functional analysis provides insight into cancer patients responses
  – James Heath, Cal Tech
• T-cell receptor diversity evaluation to predict response to ipilimumab in metastatic melanoma
  – Michael Postow, MSKCC